Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review

Plazy, Caroline; Hannani, Dalil; Gobbini, Elisa

doi:10.1007/s11912-022-01241-z

Cited by 22 publications

(14 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune checkpoint inhibitors (ICIs) have been shown to extend the survival of some cancer patients in medical oncology ( 24 ). However, several challenges exist with using ICIs to treat cancer, including low response rates ( 25 , 26 ), potential for severe adverse events( 27 , 28 ), and high costs ( 29 ). Identifying patients who are more likely to benefit from ICI treatment could save lives and improve patient outcomes( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Functional binding of PD1 ligands predicts response to anti-PD1 treatment in cancer patients

Kaufman

Abramov

Yevko

et al. 2023

Preprint

View full text Add to dashboard Cite

Accurate predictive biomarkers of response to immune checkpoint inhibitors (ICIs) are required for better stratifying cancer patients to ICI treatments. Here, we present a new concept for a bioassay to predict the response to anti-PD1 therapies, which is based on measuring the binding functionality of PDL1 and PDL2 to their receptor, PD1. In detail, we developed a cell-based reporting system, called the Immuno-checkpoint Artificial Reporter with overexpression of PD1 (IcAR-PD1) and evaluated the PDL1 and PDL2 binding functionality in tumor cell lines, patient-derived xenografts, and in fixed-tissue tumor samples obtained from cancer patients. In a retrospective clinical study, we found that the functionality of PDL1 and PDL2 predicts response to anti-PD1, and functionality of PDL1 binding is a more effective predictor than PDL1 protein expression alone. Our findings suggest that assessing the functionality of ligand binding is superior to staining of protein expression for predicting response to ICIs.

show abstract

Section: Discussionmentioning

confidence: 99%

Functional binding of PD1 ligands predicts response to anti-PD1 treatment in cancer patients

Kaufman

Abramov

Yevko

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Immune checkpoint inhibitors (ICIs) have been shown to extend the survival of some patients with cancer in medical oncology ( 23 ). However, several challenges exist with using ICIs to treat cancer, including low response rates ( 24 , 25 ), potential for severe adverse events ( 26 , 27 ), and high costs ( 28 ). Identifying patients who are more likely to benefit from ICI treatment could save lives and improve patient outcomes ( 29 ).…”

Section: Discussionmentioning

confidence: 99%

Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer

Kaufman,

Abramov,

Ievko

et al. 2023

Sci. Adv.

View full text Add to dashboard Cite

Accurate predictive biomarkers of response to immune checkpoint inhibitors (ICIs) are required for better stratifying patients with cancer to ICI treatments. Here, we present a new concept for a bioassay to predict the response to anti-PD1 therapies, which is based on measuring the binding functionality of PDL1 and PDL2 to their receptor, PD1. In detail, we developed a cell-based reporting system, called the immuno-checkpoint artificial reporter with overexpression of PD1 (IcAR-PD1) and evaluated the functionality of PDL1 and PDL2 binding in tumor cell lines, patient-derived xenografts, and fixed-tissue tumor samples obtained from patients with cancer. In a retrospective clinical study, we found that the functionality of PDL1 and PDL2 predicts response to anti-PD1 and that the functionality of PDL1 binding is a more effective predictor than PDL1 protein expression alone. Our findings suggest that assessing the functionality of ligand binding is superior to staining of protein expression for predicting response to ICIs.

show abstract

“…In addition, radiotherapy may also promote the expression of PD-L1 in tumor cells. 22 EXPERT CONSENSUS 4: FACTORS INFLUENCING THE OUTCOME OF TREATMENT WITH ICIS Among 147 experts who voted at the 6th Straits Summit Forum on Lung Cancer, 85.71% of the experts believed that previous clinical benefit was very important for the drug selection in ICI rechallenge, 62.59% chose performance score, 38.1% chose PDL1 expression degree, and 38.1% chose age…”

Section: Expert Consensus 4: Strategies In Ici Rechallengementioning

confidence: 99%

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer

Lin,

Wang,

Chu

et al. 2024

Thoracic Cancer

View full text Add to dashboard Cite

Immune checkpoint inhibitor (ICI) rechallenge in non‐small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and rechallenge becomes compulsive because of tumor relapse while the patients had completed a 2 year course of immunotherapy. However, these categories are still controversial and should be explored further. Through voting at the 6th Straits Summit Forum on Lung Cancer, in this study we summarize the consensus of 147 experts in ICI rechallenges. A total of 97.74% experts agreed to rechallenge; 48.87% experts rechallenge with the original drug, and the others rechallenge with a different drug; 40.3% agreed to rechallenge directly after progression; 88.06% experts agreed to ICI rechallenge with a combination regimen; and factors such as previous performance status score, PD‐1 expression, and age should also be considered. Understanding the the clinical studies in ICI rechallenge could bring us one step closer to understanding the consensus. In patients with advanced NSCLC who have suffered recurrent or distant metastasis after immunotherapy, the option of rechallenge with ICIs is a promising treatment option.

show abstract

Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review

Cited by 22 publications

References 75 publications

Functional binding of PD1 ligands predicts response to anti-PD1 treatment in cancer patients

Functional binding of PD1 ligands predicts response to anti-PD1 treatment in cancer patients

Functional binding of PD1 ligands predicts response to anti-PD1 treatment in patients with cancer

Rechallenge of immune checkpoint inhibitors in advanced non‐small cell lung cancer

Contact Info

Product

Resources

About